Skip to the answer

Eliglustat

Eliglustat is a once- or twice-daily capsule medicine that treats Gaucher disease type 1 in adults whose CYP2D6 genetic status fits the label.

Brand name Cerdelga
Drug class Glucosylceramide Synthase Inhibitor
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Eliglustat at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Eliglustat (Cerdelga) is a specialist capsule for Gaucher disease type 1 in adults, on the market since about 2014 and a by-mouth alternative to the usual enzyme replacement infusions; it blocks the enzyme that makes glucosylceramide, so less of this fatty substance builds up in organs. Most people tolerate it well, with mild nausea, diarrhea, upper belly pain or headache the side effects most often noticed. The one thing to watch is heart rhythm, because high levels can disturb it, so report a racing or irregular heartbeat or dizziness promptly. Those levels hinge on your CYP2D6 type (how fast your body clears it), liver and kidney health and other medicines, so every new prescription needs checking first.

Clinical pearls

  • Swallow capsules whole with water, never opened or crushed, and skip grapefruit and grapefruit juice, which raise eliglustat levels.
  • The antidepressant paroxetine and the antifungals terbinafine and ketoconazole can push levels up, so flag eliglustat whenever one is suggested.
  • If you take digoxin, expect its blood level to be checked or its dose lowered, because eliglustat can raise it.
  • It is not recommended with existing heart disease or long QT syndrome, so mention any heart history before starting.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asCapsule
Earliest FDA record2014
Companies listing it with the FDA1
FDA label last updatedMar 3, 2024
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Eliglustat, written from its FDA label.

What Eliglustat is used for

▾

Eliglustat is used for one condition, based on the Cerdelga label.

  • Cerdelga is for long-term treatment of adults with Gaucher disease type 1.
  • It is for people who are CYP2D6 extensive, intermediate or poor metabolizers, as shown by an FDA-cleared test.
  • It may not work well in ultra-rapid metabolizers.
  • No specific dose can be recommended if the CYP2D6 type can't be determined.

How Eliglustat works

▾

Gaucher disease happens when the body lacks an enzyme needed to break down a fatty substance, glucosylceramide. It builds up in cells of the liver, spleen and bone marrow. This can cause enlarged organs, bone problems, anemia and low platelets.

Eliglustat blocks glucosylceramide synthase, the enzyme that makes this substance. Less is produced, so less builds up in the organs.

Eliglustat dosage

▾

Cerdelga is a capsule taken by mouth. Your dose schedule (once or twice daily) depends on your CYP2D6 type and on other medicines you take.

  • Swallow capsules whole, preferably with water. Do not crush, dissolve or open them.
  • Take with or without food.
  • Avoid grapefruit and grapefruit juice.
  • If you miss a dose, take the next one at the usual time. Do not double up.
  • If you are switching from certain enzyme replacement therapies (imiglucerase, velaglucerase alfa or taliglucerase alfa), Cerdelga may be started 24 hours after the last dose.

Dosing details from the FDA-approved label

From the Eliglustat prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • CYP2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs)
    • 84 mg orally twice daily
    • Swallow capsules whole, preferably with water; do not crush, dissolve or open; can be taken with or without food; avoid grapefruit or grapefruit juice
  • CYP2D6 poor metabolizers (PMs)
    • 84 mg orally once daily
    • Swallow capsules whole, preferably with water; do not crush, dissolve or open; can be taken with or without food; avoid grapefruit or grapefruit juice
  • EMs and IMs with or without hepatic impairment taking CYP2D6 or CYP3A inhibitors (EMs without hepatic impairment taking a strong or moderate CYP2D6 inhibitor or a strong or moderate CYP3A inhibitor; EMs with mild (Child-Pugh Class A) hepatic impairment taking a weak CYP2D6 inhibitor or a strong, moderate, or weak CYP3A inhibitor; IMs without hepatic impairme
    • Reduce dosage frequency of CERDELGA 84 mg to once daily
    • If a dose is missed, take the prescribed dose at the next scheduled time; do not double the next dose
  • Patients currently treated with imiglucerase, velaglucerase alfa, or taliglucerase alfa
    • CERDELGA may be administered 24 hours after the last dose of the previous enzyme replacement therapy (ERT)
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Patient Selection ( 2.1 ) : Select patients using an FDA-cleared test for determining CYP2D6 genotype. Recommended Dosage Based on CYP2D6 Metabolizer Status ( 2.2 ) : EMs and IMs: 84 mg orally twice daily. PMs: 84 mg orally once daily. See the Full Prescribing Information for dosing recommendations in patients receiving CYP2D6 and/or CYP3A inhibitors, or with renal or hepatic impairment. ( 2.2 , 4 , 7.1 , 8.6 , 8.7 ) Administration ( 2.4 ) : Swallow capsules whole, do not crush, dissolve or open capsules. ( 2.4 ) Avoid eating grapefruit or drinking grapefruit juice. ( 2.4 ) 2.1 Patient Selection Select patients with Gaucher disease type 1 based on their CYP2D6 metabolizer status. It is recommended patient genotypes be established using an FDA-cleared test for determining CYP2D6 genotype [see Indications and Usage (1) ] . 2.2 Recommended Adult Dosage The recommended dosage of CERDELGA in adults is based on the patient's CYP2D6 metabolizer status. Table 1: Recommended Dosage Regimen by CYP2D6 Metabolizer Status CYP2D6 Metabolizer Status CERDELGA Dosage EMs 84 mg twice daily IMs PMs 84 mg once daily 2.3 Dosage Adjustment in EMs and IMs With or Without Hepatic Impairment and Concomitant Use of CYP2D6 or CYP3A Inhibitors Reduce dosage frequency of CERDELGA 84 mg to once daily in CYP2D6 EMs and IMs with or without hepatic impairment taking CYP2D6 or CYP3A inhibitors, as shown in Table 2 [see Warnings and Precautions (5.1) , Drug Interactions (7.1) , Use in Specific Populations (8.7) ] . Table 2: Recommended Dosage of CERDELGA 84 mg Once Daily based on CYP2D6 Metabolizer, Hepatic Impairment Status, and Concomitant CYP Inhibitors CYP2D6 Metabolizer Status Hepatic Impairment Status Concomitant CYP Inhibitor EMs Without Hepatic Impairment Taking a strong or moderate CYP2D6 inhibitor Taking a strong or moderate CYP3A inhibitor Mild (Child-Pugh Class A) Hepatic Impairment Taking a weak CYP2D6 inhibitor Taking a strong, moderate, or weak CYP3A inhibitor IMs Without Hepatic Impairment Taking a strong or moderate CYP2D6 inhibitor 2.4 Important Administration Instructions Swallow capsules whole, preferably with water, and do not crush, dissolve, or open the capsules. CERDELGA can be taken with or without food. Avoid the consumption of grapefruit or grapefruit juice (strong CYP3A inhibitors) with CERDELGA [see Drug Interactions (7.1) ] .

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Eliglustat side effects

▾

The most common side effects reported in studies were:

Common side effects

  • Fatigue
  • Headache
  • Nausea
  • Diarrhea
  • Back pain
  • Pain in arms or legs
  • Upper belly pain
  • Joint pain

When to get medical help

  • Call your doctor if you notice a racing, pounding or irregular heartbeat, palpitations or dizziness. Eliglustat may affect heart rhythm.
  • Get medical help right away if you take too much. Overdose has caused dizziness, low blood pressure, slow heart rate, nausea and vomiting.
  • Tell your doctor before starting any new medicine, since some can raise eliglustat levels and raise the risk of heart rhythm problems.
  • Tell your doctor if you develop a rash or any side effect that bothers you or does not go away.

Other reported effects included joint pain, dizziness, weakness, heartburn or reflux, constipation, rash and palpitations. Call your doctor about heart rhythm symptoms or anything severe or persistent.

Eliglustat warnings and precautions

▾

Heart rhythm risk is the main concern. Eliglustat can lengthen the PR, QTc and QRS intervals on an ECG at high blood levels, which may lead to abnormal heart rhythms.

  • Avoid it with existing heart disease (heart failure, recent heart attack, slow heart rate, heart block, ventricular arrhythmia).
  • Avoid it in long QT syndrome and with Class IA or Class III heart rhythm drugs.
  • Heart disease was not studied in clinical trials.
  • Some CYP2D6 types, liver problems and interacting drugs raise levels and may make it contraindicated.

Eliglustat interactions

▾

Many interactions work by raising or lowering eliglustat levels.

  • CYP2D6 inhibitors (such as paroxetine, terbinafine) can raise levels, which raises heart rhythm risk.
  • CYP3A inhibitors (such as ketoconazole) can raise levels. Some combinations are contraindicated.
  • Grapefruit and grapefruit juice act as CYP3A inhibitors, so avoid them.
  • Strong CYP3A inducers can lower levels and reduce effectiveness. Avoid them.
  • Digoxin levels may rise. Your doctor may check levels and lower the digoxin dose.
  • Other P-gp or CYP2D6 drugs may also rise and may need monitoring or dose changes.

Interactions listed in the FDA-approved label

From the Eliglustat prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • CYP2D6 inhibitors (strong, moderate, weak): May increase eliglustat concentrations, which may increase the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac interval. EMs with strong or moderate inhibitor: reduce CERDELGA 84 mg to once daily; IMs: continue 84 mg once daily with strong or moderate inhibitor; weak inhibitor: continue 84 mg twice daily. No effect in PMs due to little or no CYP2D6 activity.
  • CYP3A inhibitors (strong, moderate, weak): May increase eliglustat concentrations, which may increase the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac interval. EMs: strong inhibitor, reduce CERDELGA 84 mg to once daily; moderate, avoid coadministration; weak, continue 84 mg twice daily. IMs: strong, contraindicated. Weak: avoid coadministration.
  • Grapefruit or grapefruit juice (strong CYP3A inhibitors): Classed as strong CYP3A inhibitors. Avoid the consumption of grapefruit or grapefruit juice with CERDELGA.
  • CYP2D6 inhibitor taken concomitantly with a strong CYP3A inhibitor: May increase eliglustat concentrations and the risk of cardiac arrhythmias. Strong CYP2D6 inhibitor: contraindicated. Moderate CYP2D6 inhibitor: contraindicated.
  • CYP2D6 inhibitor taken concomitantly with a moderate CYP3A inhibitor: May increase eliglustat concentrations and the risk of cardiac arrhythmias. Strong CYP2D6 inhibitor: contraindicated. Moderate CYP2D6 inhibitor: avoid coadministration.
  • Strong CYP3A inducers: Decrease eliglustat concentrations, which may reduce CERDELGA efficacy. Avoid coadministration.
  • Digoxin: CERDELGA may increase concentrations of digoxin (a P-gp substrate) and may increase the risk of its toxicity. Monitor serum digoxin concentrations before initiating CERDELGA. Reduce digoxin dose by 30% and continue monitoring.
  • Other P-gp substrates or CYP2D6 substrates: CERDELGA may increase concentrations of these drugs and may increase the risk of their toxicity. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.
Read the label’s full interactions text

7 DRUG INTERACTIONS See Full Prescribing Information for a list of clinically significant drug interactions. ( 7.1 , 7.2 ) 7.1 Effect of Other Drugs on CERDELGA Coadministration of CERDELGA with: CYP2D6 or CYP3A inhibitors may increase eliglustat concentrations which may increase the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac interval [see Warnings and Precautions (5.1) , Clinical Pharmacology (12.3) ] . strong CYP3A inducers decrease eliglustat concentrations which may reduce CERDELGA efficacy [see Clinical Pharmacology (12.3) ] . See Table 5 for prevention and management of interactions with drugs affecting CERDELGA. Use of CERDELGA is contraindicated, to be avoided, or may require dosage adjustment depending on the concomitant drug and CYP2D6 metabolizer status [see Dosage and Administration (2.2 , 2.3) , Contraindications (4) , Drug Interactions (7.1) ] . Table 5: Prevention and Management Strategies of Drug Interactions Affecting CERDELGA Based on CYP2D6 Metabolizer Status and Concomitant Interacting Drug Concomitant Drug(s) CYP2D6 Metabolizer Status EMs IMs PMs CYP2D6 Inhibitor Strong Reduce frequency of CERDELGA 84 mg to once daily Continue CERDELGA 84 mg once daily No effect of CYP2D6 inhibitor due to little or no CYP2D6 activity in CYP2D6 PMs. Moderate Weak Continue CERDELGA 84 mg twice daily CYP3A Inhibitor Strong Reduce frequency of CERDELGA 84 mg to once daily Contraindicated Moderate Avoid coadministration Weak Continue CERDELGA 84 mg twice daily Avoid coadministration CYP2D6 Inhibitor Concomitantly with a strong CYP3A Inhibitor Strong Contraindicated Moderate CYP2D6 Inhibitor Concomitantly with a moderate CYP3A Inhibitor Strong Contraindicated Avoid coadministration Moderate CYP3A Inducer Strong Avoid coadministration 7.2 Effect of CERDELGA on Other Drugs See Table 6 for clinically relevant interactions affecting P-gp or CYP2D6 substrates when coadministered with CERDELGA.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿146 supplements and herbs with documented Eliglustat interactions, ranked by severity Check Eliglustat against a supplement or herb →

Before taking Eliglustat

▾
  • You need a CYP2D6 genetic test before starting.
  • Do not use it if you have liver impairment in certain groups: moderate or severe in extensive metabolizers, and any degree in intermediate or poor metabolizers.
  • Mild liver impairment with some interacting drugs is also contraindicated.
  • Avoid it in intermediate and poor metabolizers with any kidney impairment, and in extensive metabolizers with end-stage kidney disease.
  • Tell your doctor about heart conditions and long QT syndrome.
  • Pregnancy: human data are insufficient, and animal studies showed harm at high doses. Untreated Gaucher disease also carries pregnancy risks.
  • Breastfeeding: no human data. Eliglustat was found in rat milk.
  • Not established for children.
  • Not enough people 65 and over were studied to know whether they respond differently.

Eliglustat overdose

▾

In one healthy volunteer given about 21 times the recommended dose, effects included dizziness with loss of balance, low blood pressure, slow heart rate, nausea and vomiting. In an overdose, the person should be watched closely and given supportive treatment. Hemodialysis is unlikely to help.

What Eliglustat does in the body

▾

In people not previously treated, improvements in spleen and liver size, hemoglobin and platelets increased as eliglustat levels rose. At very high levels, ECG intervals (PR, QRS, QTc) lengthen. At eight times the recommended dose, no clinically relevant QT prolongation was seen. Modeling predicts greater increases at very high blood levels.

How your body processes Eliglustat

▾

Only a small fraction of an oral dose reaches the bloodstream (under 5% in extensive metabolizers). Food does not meaningfully change how much is absorbed. The body breaks eliglustat down mainly through CYP2D6, and to a lesser extent CYP3A4. Poor metabolizers have 7- to 9-fold higher exposure than extensive metabolizers. Half-life is about 6.5 hours in extensive metabolizers and 8.9 hours in poor metabolizers. Most of the dose leaves as metabolites in urine and feces.

How to store Eliglustat

▾

Store at 68°F–77°F (20°C–25°C) with excursions permitted between 59°F and 86°F (15°C to 30°C) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

146

Supplements & herbs that interact with Eliglustat

146 supplements and herbal products have documented interactions with Eliglustat in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 8
  • Moderate · 98
  • Minor · 40
ACTIVATED CHARCOAL Major AMERICAN HELLEBORE Major ARSENIC Major CESIUM Major EPHEDRA Major GRAPEFRUIT Major SIDA CORDIFOLIA Major ST. JOHN'S WORT Major +138 more
Every supplement checked against Eliglustat — ranked by severity The full interaction hub: 8 major · 98 moderate · 40 minor · every one linked to its full report. Check Eliglustat against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Eliglustat: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Eliglustat — the kind of thing our pharmacy team would talk through with you at the counter.

What is this medicine for?

▾
Eliglustat, sold as Cerdelga, treats Gaucher disease type 1 in adults. It lowers production of the fatty substance that builds up in your organs with this condition. You need a CYP2D6 genetic test first to confirm it's right for you.

How should I take my capsules?

▾
Swallow them whole, preferably with water. Don't crush, open or dissolve them. You can take them with or without food. If you miss a dose, just take the next one at the usual time and don't double up.

Can I eat grapefruit?

▾
No, avoid grapefruit and grapefruit juice. They can raise the amount of eliglustat in your body, which may increase the risk of heart rhythm problems.

What side effects should I expect?

▾
The most common are fatigue, headache, nausea, diarrhea, back pain, pain in your arms or legs and upper belly pain. Call your doctor if you notice a pounding, fast or irregular heartbeat, or if any side effect is severe or won't go away.

Do I need to worry about my other medicines?

▾
Yes, tell me and your doctor about everything you take, including over-the-counter products and supplements. Some medicines raise eliglustat levels and heart rhythm risk, and others lower how well it works. Some combinations aren't allowed, and others need your dosing changed.

Is it safe in pregnancy?

▾
There isn't enough human data to know the risk. Animal studies showed problems at high doses. Untreated Gaucher disease also carries risks in pregnancy, so talk with your doctor if you're pregnant or planning to be.

Is Eliglustat available over the counter?

▾
No. Eliglustat is a prescription medicine: every Eliglustat product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Eliglustat first available?

▾
The earliest FDA record we hold for Eliglustat is from 2014: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Eliglustat was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Eliglustat on HelloPharmacist

📊Eliglustat supplement interactions146 checked — ranked by severity 🌿Drug & Supplement CheckerEliglustat vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Eliglustat NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Eliglustat Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Eliglustat forms and strengths (how it comes)

Eliglustat is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Capsule

By mouth
Brands Cerdelga
How this form is used
What it may be used for
  • Cerdelga is used for long-term treatment of adults with Gaucher disease type 1 who are CYP2D6 extensive, intermediate or poor metabolizers.
Important instructions
  • Cerdelga capsules should be swallowed whole, preferably with water. Do not crush, dissolve or open them.
  • Cerdelga can be taken with or without food.
  • Avoid grapefruit and grapefruit juice while taking Cerdelga.
  • If you miss a Cerdelga dose, take the next dose at the scheduled time. Do not double it.
Available strengths 1 strength
84 mg
3 FDA-listed product records ⓘ

Eliglustat on the U.S. market: products, makers and brands

How Eliglustat appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Eliglustat product record with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2014. Brand names on the directory include Cerdelga; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
1
FDA-listed product records ⓘ
2014
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (7) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

How widely Eliglustat is used (Medicaid data)

A general measure of how commonly Eliglustat is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Eliglustat is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

453
Medicaid prescriptions filled (Q1–Q4 2025)
$15.3M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Eliglustat prescribed? Of the 1,601 medications we measure, Eliglustat ranks #1,372 by Medicaid prescriptions — more than 14% of them.

Where Eliglustat ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,372 of 1,601
#1,367 Disopyramide 467 Rx #1,368 Pazopanib 466 Rx #1,369 Cefuroxime Injection 465 Rx #1,370 Satralizumab-mwge Inje... 462 Rx #1,371 Siponimod 459 Rx #1,372 Eliglustat 453 Rx #1,373 Interferon Gamma-1b In... 438 Rx #1,374 Olanzapine Injection 436 Rx #1,375 Demeclocycline 434 Rx #1,376 Peginterferon Alfa-2a... 431 Rx #1,377 Levoleucovorin Injecti... 424 Rx

Utilization by Eliglustat product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

eliglustat 84 MG Oral Capsule

453 Medicaid prescriptions (Q1–Q4 2025) 100% of Eliglustat prescriptions shown $15.3M gross reimbursement (before rebates) ≈ $33,807 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1547225

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Eliglustat, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 2 listed Eliglustat NDCs with Medicaid activity.

Compare Eliglustat products

A representative set of FDA-listed product records for Eliglustat — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Capsule
84 mg Oral Genzyme Corporation NDA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Eliglustat NDCs →

Eliglustat recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Eliglustat recalls since July 2021.

✅No Eliglustat recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Eliglustat RxCUI 1547220 1 dose form · 1 strength
  1. Dose form (SCDF) Oral Capsule RxCUI 1547224 In current FDA listings
    Clinical drug / strength (SCD) 84 MG RxCUI 1547225

Look up RxCUI 1547220 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Eliglustat brand names

Eliglustat is sold under one brand name in the FDA directory — Cerdelga. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Cerdelga

Who makes Eliglustat: manufacturers and labelers

One company lists Eliglustat products with the FDA. By number of product records, the largest are Genzyme Corporation. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Genzyme Corporation 1

Eliglustat drug class (RxNorm)

Eliglustat belongs to the Glucosylceramide Synthase Inhibitor class.

Pharmacologic class Glucosylceramide Synthase Inhibitor
Drug family (ATC) Various alimentary tract and metabolism products
How it works Glucosylceramide Synthase Inhibitors, Cytochrome P450 2D6 Inhibitors, P-Glycoprotein Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Eliglustat page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Mar 3, 2024
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Eliglustat.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Eliglustat after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Genzyme Corporation
Linked label effective
Mar 3, 2024
Composite sections available
23
Linked SPL Set ID
819f828a-b888-4e46-83fc-94d774a28a83
Linked SPL Document ID
e71b0b39-5a29-4e38-8500-55b6d1f48543
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Genzyme Corporation is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →